Article Sidebar

PDF
Date Published: 28/06/2025
Abstract Views: 4
Views PDF: 4
DOI: https://doi.org/10.56535/jmpm.v50i5.1248
Issue
Vol. 50 No. 5 (2025): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 5 - 2025
Section
Articles
How to Cite
Ngo, T. H., & Cấn, V. M. (2025). Study on optimizing production of CAR-T cell mass. Journal of Military Pharmaco-medicine, 50(5), 36-43. https://doi.org/10.56535/jmpm.v50i5.1248

Study on optimizing production of CAR-T cell mass

Ngo Thu Hang1, Văn Mão Cấn2,
1 Vietnam Medical Military University
2 Bộ môn Sinh lý bệnh, Học viện Quân y

Main Article Content

Abstract

Objective: Optimizing the co-culture process of CAR-T cells and aAPC 1D2 to obtain the highest quantity and quality of CAR-T cells. Subjects and methods: Separating PBMC from fresh blood samples. Then PBMC was analyzed by BD Facslyric flow cytometer. Transposition into PBMC using Amaxa Nucleofector 2b with T-020 program. Co-culture CAR-T and aAPC at a ratio of 2X viable CAR-T cells. CAR expression was analyzed by real-time PCR. Results: On 7th and 14th day, the number of CAR-T cells proliferated many times higher than that on 3rd day. The proliferative capacity of the two CAR-T cell generations was similar on 14th day and there was a difference of that from day 21. After 28th day, the number of iCasp9-IL15 CAR-T cells (78.62%) was higher than that of CD19RCD137 CAR-T cells (66.23%) with p>0.05. The results on day 28 showed that approximately 97% of CAR-T cells of both cell generations expressed CAR on the surface after proliferation. Conclusion: CAR-T cells proliferated effectively from 28th day on co-culture with artificial antigen-presenting cells and IL-2 with aAPC supplementation of 4 times (1st, 7th, 14th, 21st day). the obtained cells expressed CAR molecules of 97% on the surface.

Article Details

Keywords

CAR-T cells, PBMC cell and transposition.

References

1. Chen L, Flies DBJNri. Molecular mechanisms of T cell co-stimulation and co-inhibition. 2013; 13(4):227-242.
2. Levine BJCgt. (2015). Performance- enhancing drugs: Design and production of redirected chimeric antigen receptor (CAR) T cells. 2015; 22(2):79-84.
3. Deeks SG, Wagner B, Anton PA, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. 2002; 5(6):788-797.
4. Vormittag P, Gunn R, Ghorashian S, et al. A guide to manufacturing CAR T cell Therapies. 2018; 53:164-181.
5. Wang H, Du X, Chen WH, et al. Establishment of a quantitative polymerase chain reaction assay for monitoring chimeric antigen receptor T cells in peripheral blood. Transplantation Proceedings. 2018; 50(1):104-109.
6. Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. 2017; 25(1):285-295.
7. Gargett T, Brown MPJC. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. 2015; 17(4):487-495.
8. Singh H, Figliola MJ, Dawson MJ, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. 2013; 8(5):e64138.